Dipharma Francis S.r.l. completes acquisition of Kalexsyn, Inc.
Published: May 17, 2018
With revenues exceeding USD 125 million, Dipharma is one of the leading family-owned European manufacturers of Active Pharmaceutical Ingredients. Its three manufacturing sites located in northern Italy have been successfully inspected by the major health authorities since 1970. The Company develops innovative chemical processes and crystalline forms for the most renowned pharmaceutical companies in USA, Europe, Japan, and other regions of the globe. Its manufacturing facilities supply from laboratory to industrial quantities whilst complying fully with the most stringent quality standards.
About Kalexsyn, Inc.
Kalexsyn is a world-class chemistry CRO, whose scientists average 15 years’ experience in hit validation, lead optimization and solving tough synthetic problems. It provides stable label synthesis, custom synthesis, process impurity synthesis, and process route development to its world-wide clients. Kalexsyn offers an outstanding CRO experience with fixed quote as well as short and long-term FTE arrangements. The Company has research laboratories in Kalamazoo, Michigan.
Source: Kalexsyn, Inc.